Researchers at Fundación Pérez Scremini in Montevideo, Uruguay, have implemented and operationally assessed a multiparametric flow cytometry workflow designed for monitoring anti-CD19 chimeric antigen receptor T (CAR-T) cells within an academic point-of-care cellular therapy program. Reporting in a methods study published in Frontiers in Hematology, the investigative team established the laboratory protocol to provide direct detection of circulating CAR-T cells, offering information complementary to B-cell aplasia during recipient immune monitoring following cellular therapy.
The established assay was structured to serve two operational checkpoints: product quality control of manufactured CAR-T cells and ongoing post-infusion monitoring in patients. To implement the technical workflow, the researchers utilized an eight-color production panel alongside a locally adapted clinical monitoring panel configured on a thirteen-color DxFLEX cytometer.
Direct identification of the therapeutic cells relied on a biotinylated CD19 CAR Detection Reagent paired with phycoerythrin-conjugated anti-biotin antibodies. During assay optimization, the team evaluated reagent titration, specific gating strategies, and signal-to-noise performance alongside reagent consumption. From these evaluations, an operational working condition of two microliters of CD19 CAR Detection Reagent and two microliters of PE-conjugated anti-biotin was selected to balance staining clarity with reagent stewardship in routine practice.
In parallel with direct cell tracking, the comprehensive monitoring strategy incorporated an assessment of the patient B-cell compartment using a separate ten-color tube to detect B-cell aplasia. Beyond enumerating the presence of CAR-positive cells, the analytical workflow successfully characterized phenotypic subpopulations within the circulating graft, specifically distinguishing the distribution of CD4 and CD8 subsets among the detected CAR-positive lymphocytes.
To interpret low-frequency cell populations with statistical rigor, the team incorporated an analytical sensitivity framework with defined event thresholds. The established criteria specified a limit of blank of 8 events, a limit of detection of 13 events, and a lower limit of quantification of 22 events. The authors noted that these sensitivity benchmarks were adopted directly from previously published validation criteria rather than derived through an independent, complete local recalculation.
The operational workflow was successfully integrated into routine laboratory practice and utilized during the initial clinical phase of Uruguay’s point-of-care cellular therapy program. The investigators concluded that flow cytometry established an integrated, locally available monitoring platform combining direct CAR-T quantification with phenotypic and B-cell profiling, offering practical operational insights for academic cellular therapy initiatives operating under comparable resource and technical implementation conditions.
Subject of Research: Flow cytometric immune monitoring of anti-CD19 CAR-T cells
Article Title: Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment
Article References: Barrios, M., Pereira Pereyra, M. I., Ceriani, V., DAndrea, L., & Castillo, L. (2026). Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment. Frontiers in Hematology, 5, 2007169. https://doi.org/10.3389/frhem.2026.2007169
Image Credits: AI Generated
DOI: 10.3389/frhem.2026.2007169
Keywords: anti-CD19 CAR-T cells, flow cytometry, immune monitoring, B-cell aplasia, cellular therapy, point-of-care program, DxFLEX cytometer, CD19 CAR Detection Reagent, PE-conjugated anti-biotin, reagent titration, gating strategy, limit of blank, limit of detection, lower limit of quantification, CD4/CD8 distribution, T-cell phenotype, Uruguay
News Source: Ophelia Keating. (November 16, 2026). Flow Cytometry Workflow Monitors Anti-CD19 CAR-T Cells in Uruguayan Academic Program. Scienmag.



